Using Taurine to Prevent and Treat Skin Damage from Radiation in Breast Cancer Patients
Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
This study is testing whether applying taurine on the skin can help breast cancer patients prevent and heal skin damage caused by radiation treatment.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Shandong Cancer Hospital and Institute Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06847555 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the safety and efficacy of taurine applied externally to prevent and treat acute radiation skin injuries in breast cancer patients undergoing adjuvant radiotherapy. The study aims to address the common side effects of radiation therapy, which can significantly impact patients' quality of life. By focusing on patients scheduled for conventional fractionated radiotherapy, the trial seeks to provide a potential solution for those experiencing severe skin damage. Participants will be monitored for their response to the treatment throughout the phases of the trial.
Who should consider this trial
Good fit: Ideal candidates include breast cancer patients aged 18 and older who are scheduled for adjuvant radiotherapy and have an ECOG score of 0-1.
Not a fit: Patients with serious organ diseases, those who are pregnant or lactating, or individuals allergic to taurine will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce skin injuries caused by radiation therapy, improving patient comfort and quality of life.
How similar studies have performed: While there is limited data on the use of taurine for this specific purpose, similar studies exploring skin protection during radiation therapy have shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer patients scheduled for conventional fractionated adjuvant * radiotherapy. * 18 years or older * ECOG score 0-1 * No previous history of other neoplasms. * No previous chest radiotherapy. * Heart, lung function, liver function and kidney function were within normal range. * Voluntary informed consent. Exclusion Criteria: * Pregnant or lactating women, women in childbearing years who do not use effective contraception； * Patients with mental disease or nervous system disease, unable to clearly describe treatment response (such as cerebrovascular accident sequela); * Those who have serious heart, liver, kidney and other organ diseases or diabetes and are not expected to complete the treatment plan; * serious, uncontrolled diseases and infections; * Pregnant or lactating patients. * Allergic to taurine and any of its components. * Has participated in other clinical trials. * knot tissue disease * active hepatitis * Obvious diseases that the investigator considers should be excluded from this study
Where this trial is running
Jinan, Shandong
- Shandong Cancer Hospital — Jinan, Shandong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.